Nebenwirkungen · Riximyo
Riximyo 100 mg concentrate for solution for infusion Riximyo 500 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24–25
HOS-141065 · Präparat HOS-098602
24 exposure to rituximab. The incidence of IRRs declined with subsequent infusions. In clinical trials fewer than 1% (17/3 189) of patients experienced a serious IRR. There were no CTC Grade 4 IRRs and no deaths due to IRRs in the clinical trials. The proportion of CTC Grade 3 events and of IRRs leading to withdrawal decreased by course and were rare from course 3 onwards. Premedication with intravenous glucocorticoid significantly reduced the incidence and severity of IRRs (see sections 4.2 and 4.4). Severe IRRs with fatal outcome have been reported in the post-marketing setting.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-04T16:41:00Z · SHA-256 4fe21e50fef50537643123868d3f044762b7d55eab7d50a56c1d469305291ee4 · Passage 96848ac1c0d08a93427d4938a06a29f658ce6e0f55bc05eaf75bcdda9f0b780a · Zeichen 35555–36143 im Abschnitt